Related Experiment Video
Updated: Jan 28, 2026

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Pseudomyxoma Peritonei: Presentation of Two Cases and Challenging Issues in the Literature
Eirini V Pantiora1, Dimitrios Massaras1, John Koutalas2
1Surgery, Aretaieio Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, GRC.
Abstract:
Pseudomyxoma peritonei (PMP) is a rather uncommon syndrome in oncology with a unique biological behavior and an estimated incidence of one to two cases per million per year. Clinically, it usually presents with a variety of unspecific signs and symptoms including abdominal pain and distention, ascites, or even bowel obstruction. Despite its intimidating clinical manifestation, PMP is characterized by satisfactory survival rates when treated with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). We present two interesting cases of PMP deriving from the appendix with a rather atypical presentation, which was successfully treated with cytoreduction and HIPEC. In addition, we intend to raise clinical suspicion on the diagnosis of PMP and comment on several challenging issues concerning the origin and classification of PMP.
Insights
Pseudomyxoma peritonei (PMP), a rare oncology syndrome, typically presents with vague symptoms. However, this study highlights successful treatment of two appendix-derived PMP cases using cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Area of Science:
- Oncology
- Gastroenterology
Background:
- Pseudomyxoma peritonei (PMP) is a rare oncology syndrome with an incidence of 1-2 cases per million annually.
- PMP often presents with nonspecific symptoms like abdominal pain, distention, ascites, or bowel obstruction.
Observation:
- This report details two cases of PMP originating from the appendix with atypical clinical presentations.
- Both cases were successfully managed using cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
Findings:
- Cytoreduction and HIPEC demonstrate satisfactory survival rates for PMP, even with unusual presentations.
- The study emphasizes the importance of raising clinical suspicion for PMP.
Implications:
- Early diagnosis and appropriate treatment, including cytoreduction and HIPEC, are crucial for managing PMP.
- Further discussion on the origin and classification of PMP is warranted to address challenging issues in its management.
Related Concept Videos
Self-Presentation
Self-Presentation: Self-Monitoring and Self-Handicapping
Strategies of Self-Presentation I: Strategic Self-Presentation
Processes of Self-Presentation
Ethical Issues
Ethical Concerns in Healthcare:
Strategies of Self-Presentation II: Self-Verification

